Resistant Hypertension, Secondary Hypertension, and Hypertensive Crises: Diagnostic Evaluation and Treatment

被引:42
作者
Acelajado, Maria Czarina [1 ]
Calhoun, David A. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA
关键词
Resistant hypertension; Secondary hypertension; Malignant hypertension; Diagnosis; Treatment; AMBULATORY BLOOD-PRESSURE; OBSTRUCTIVE SLEEP-APNEA; PLASMA-ALDOSTERONE; ANTIHYPERTENSIVE THERAPY; WHITE SUBJECTS; DRUG-THERAPY; SPIRONOLACTONE; PREVALENCE; RISK; HYPERALDOSTERONISM;
D O I
10.1016/j.ccl.2010.07.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension is a very common modifiable risk factor for cardiovascular morbidity and mortality. Patients with hypertension represent a diverse group. In addition to those with primary hypertension, there are patients whose hypertension is attributable to secondary causes, those with resistant hypertension, and patients who present with a hypertensive crisis. Secondary causes of hypertension account for less than 10% of cases of elevated blood pressure (BP), and screening for these causes is warranted if clinically indicated. Patients with resistant hypertension, whose BP remains uncontrolled in spite of use of 3 or more antihypertensive agents, are at increased cardiovascular risk compared with the general hypertensive population. After potentially correctible causes of uncontrolled BP (pseudoresistance, secondary causes, and intake of interfering substances) are eliminated, patients with true resistant hypertension are managed by encouraging therapeutic lifestyle changes and optimizing the antihypertensive regimen, whereby the clinician ensures that the medications are prescribed at optimal doses using drugs with complementary mechanisms of action, while adding an appropriate diuretic if there are no contrain-dications. Mineralocorticoid receptor antagonists are formidable add-on agents to the antihypertensive regimen, usually as a fourth drug, and are effective in reducing BP even in patients without biochemical evidence of aldosterone excess. In the setting of a hypertensive crisis, the BP has to be reduced within hours in the case of a hypertensive emergency (elevated BP with evidence of target organ damage) using parenteral agents, and within a few days if there is hypertensive urgency, using oral antihypertensive agents.
引用
收藏
页码:639 / +
页数:17
相关论文
共 87 条
  • [1] [Anonymous], 1990, Circulation, V82, P1616
  • [2] [Anonymous], 2004, Am J Kidney Dis, V43, pS1
  • [3] Antihypertensive T., 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI [10.1001/jama.288.23.2981, DOI 10.1001/JAMA.288.23.2981]
  • [4] Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients
    Avanzini, F
    Palumbo, G
    Alli, C
    Roncaglioni, MC
    Ronchi, E
    Cristofari, M
    Capra, A
    Rossi, S
    Nosotti, L
    Costantini, C
    Pietrofeso, R
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (06) : 611 - 616
  • [5] Benchetrit S, 2002, ISRAEL MED ASSOC J, V4, P17
  • [6] Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
    Bianchi, S
    Bigazzi, R
    Campese, VM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (01) : 45 - 51
  • [7] Usefulness of the vasodilator minoxidil in resistant hypertension
    Black, R. Neil A.
    Hunter, Steven J.
    Atkinson, A. Brew
    [J]. JOURNAL OF HYPERTENSION, 2007, 25 (05) : 1102 - 1103
  • [8] Monitoring compliance in resistant hypertension: an important step in patient management
    Burnier, M
    Santschi, V
    Favrat, B
    Brunner, HR
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 : S37 - S42
  • [9] Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea
    Calhoun, DA
    Nishizaka, MK
    Zaman, MA
    Harding, SM
    [J]. CHEST, 2004, 125 (01) : 112 - 117
  • [10] Hyperaldosteronism among with resistant black and white subjects hypertension
    Calhoun, DA
    Nishizaka, MK
    Zaman, MA
    Thakkar, RB
    Weissmann, P
    [J]. HYPERTENSION, 2002, 40 (06) : 892 - 896